Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
$63.22
$63.22
$63.22
$63.22
$24.43B0.26279 shsN/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$490.81
+0.0%
$436.37
$250.05
$501.30
$13.79B1.44439,165 shs59,974 shs
National Research Corporation stock logo
NRC
National Research
$16.15
+0.5%
$14.94
$9.76
$22.99
$372.30M0.4793,344 shs16,832 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
-30.2%
$0.00
$0.00
$0.10
$2.04M1.08126,301 shs28,071 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
0.00%0.00%0.00%0.00%+3.36%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
-1.14%+1.07%+7.19%+62.14%+37.59%
National Research Corporation stock logo
NRC
National Research
-0.86%-0.50%+4.90%-4.58%-27.63%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
+51.43%+51.43%+152.38%+152.38%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
$63.22
$63.22
$63.22
$63.22
$24.43B0.26279 shsN/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$490.81
+0.0%
$436.37
$250.05
$501.30
$13.79B1.44439,165 shs59,974 shs
National Research Corporation stock logo
NRC
National Research
$16.15
+0.5%
$14.94
$9.76
$22.99
$372.30M0.4793,344 shs16,832 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
-30.2%
$0.00
$0.00
$0.10
$2.04M1.08126,301 shs28,071 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
0.00%0.00%0.00%0.00%+3.36%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
-1.14%+1.07%+7.19%+62.14%+37.59%
National Research Corporation stock logo
NRC
National Research
-0.86%-0.50%+4.90%-4.58%-27.63%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
+51.43%+51.43%+152.38%+152.38%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
0.00
N/AN/AN/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
1.94
Reduce$422.27-13.96% Downside
National Research Corporation stock logo
NRC
National Research
0.00
N/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MEDP, BTGGF, NRC, and SRNE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2025
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$400.00 ➝ $450.00
9/3/2025
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Rothschild Redb
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
9/3/2025
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyNeutral$342.00 ➝ $474.00
7/29/2025
Medpace Holdings, Inc. stock logo
MEDP
Medpace
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutralSell$300.00 ➝ $305.00
7/25/2025
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$328.00 ➝ $510.00
7/23/2025
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuySell
7/23/2025
Medpace Holdings, Inc. stock logo
MEDP
Medpace
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
7/23/2025
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$298.00 ➝ $436.00
7/23/2025
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$270.00 ➝ $430.00
7/23/2025
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$300.00 ➝ $450.00
(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/AN/AN/AN/AN/AN/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$2.11B6.54$13.79 per share35.58$26.56 per share18.48
National Research Corporation stock logo
NRC
National Research
$143.06M2.60$1.33 per share12.14$1.36 per share11.87
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M0.03N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/AN/A0.00N/AN/AN/AN/AN/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$404.39M$13.4536.4935.933.1218.74%67.66%21.86%10/20/2025 (Estimated)
National Research Corporation stock logo
NRC
National Research
$24.78M$0.7621.24N/A12.78%83.52%18.05%10/24/2025 (Estimated)
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84MN/A0.00N/AN/AN/AN/AN/A

Latest MEDP, BTGGF, NRC, and SRNE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/28/2025Q2 2025
National Research Corporation stock logo
NRC
National Research
N/A$0.28N/A-$0.01N/A$34.04 million
7/21/2025Q2 2025
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$3.00$3.10+$0.10$3.10$537.70 million$603.31 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/AN/AN/AN/AN/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/AN/AN/AN/AN/A
National Research Corporation stock logo
NRC
National Research
$0.482.97%N/A63.16%N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A

Latest MEDP, BTGGF, NRC, and SRNE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/23/2025
National Research Corporation stock logo
NRC
National Research
quarterly$0.123.6%9/26/20259/26/202510/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/AN/AN/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/A
0.43
0.43
National Research Corporation stock logo
NRC
National Research
3.61
0.70
0.70
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
77.98%
National Research Corporation stock logo
NRC
National Research
47.26%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%

Insider Ownership

CompanyInsider Ownership
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
N/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
20.30%
National Research Corporation stock logo
NRC
National Research
2.00%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bitcoin Group SE stock logo
BTGGF
Bitcoin Group
35386.49 millionN/ANot Optionable
Medpace Holdings, Inc. stock logo
MEDP
Medpace
5,90028.09 million22.39 millionOptionable
National Research Corporation stock logo
NRC
National Research
49023.06 million22.60 millionOptionable
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
800551.28 million536.95 millionNo Data

Recent News About These Companies

Sorrento Therapeutics Inc (SRNE) - Investing.com
SRNE Sorrento Therapeutics, Inc. - Seeking Alpha
Sorrento Shareholders Lose Discovery Bid Over Judge Relationship
Sorrento Therapeutics Inc (SRNE)
Sorrento Therapeutics Inc SRNE
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
Sorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)
Sorrento Therapeutics
5 Sanders Cove, Sorrento WA 6020

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bitcoin Group stock logo

Bitcoin Group OTCMKTS:BTGGF

$63.22 0.00 (0.00%)
As of 09/16/2025

Bitcoin Group SE, an investment holding company, engages in the cryptocurrency and blockchain businesses worldwide. The company operates a trading platform for the digital currency bitcoin under the Bitcoin.de. It also provides financial services. The company was founded in 2008 and is based in Herford, Germany. Bitcoin Group SE is a subsidiary of Priority AG.

Medpace stock logo

Medpace NASDAQ:MEDP

$490.80 +0.04 (+0.01%)
As of 12:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

National Research stock logo

National Research NASDAQ:NRC

$16.14 +0.09 (+0.53%)
As of 12:40 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.

Sorrento Therapeutics stock logo

Sorrento Therapeutics NASDAQ:SRNE

$0.0037 0.00 (-30.19%)
As of 12:05 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.